Treatment of obstetric and gynecologic infections with meropenem: Comparison with imipenem/cilastatin

Journal of Chemotherapy

Volumn 10, Issue 2, 1998, Pages 114-121

  Maggioni, P ^a   Di Stefano, F ^b   Facchini, V ^c   Irato, S ^d   Mancuso, S ^e   Colombo, M ^f   Massobrio, M ^g   Melis, G B ^h   Crosignani, P ^a,i  

^a Clinica Ostetrica e Ginecologica   (Italy)

^b I Divisione di Diagnosi e Cura   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

^f SAN GERARDO HOSPITAL   (Italy)

^g MAURIZIANO HOSPITAL   (Italy)

^h S Giovanni di Dio Hospital   (Italy)

ⁱ UNIVERSITY OF MILAN   (Italy)

Author keywords

Cilastatin; Imipenem; Infection; Meropenem; Obstetric and gynecologic

Indexed keywords

CILASTATIN; IMIPENEM; MEROPENEM;

ADNEXITIS; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATION; BACTEROIDES; CELLULITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENDOMETRITIS; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FEMALE; GARDNERELLA VAGINALIS; GYNECOLOGIC INFECTION; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KLEBSIELLA OXYTOCA; LACTOBACILLUS BIFIDUS; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MOBILUNCUS; MORAXELLA; MULTICENTER STUDY; MYCOPLASMA; NAUSEA; ORTHOSTATIC HYPOTENSION; OVARY ABSCESS; PELVIC INFLAMMATORY DISEASE; PERITONITIS; RANDOMIZED CONTROLLED TRIAL; RASH; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; VAGINA CANDIDIASIS; VOMITING;

EID: 0031944026     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1998.10.2.114     Document Type: Article

References (27)

1. Edwards JR. Meropenem: a microbiological overview. J Antimicrob Chemother 1995; 36 (suppl A): 1-17.
2. Tonelli F. Meropenem (Merrem®) vs imipenem/cilastatina nel trattamento ospedaliero delle infezioni intra-addominali. Studio multicentrico. Minerva Chir 1997; 52: 317-326.
3. Geroulanos SJ and the Meropenem Study Group. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. J Antimicrob Chemother 1995; 36 (suppl A): 191-205.
4. Condon RE, Walker AP, Sirinek KR et al. Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis 1995; 21: 544-550.
5. Huizinga WKJ, Warren BL, Baker LW et al. Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. J Antimicrob Chemother 1995; 36 (suppl A): 179-189.
6. Colardyn F, Faulkner KL (Meropenem Serious Infection Study Group). Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. J Antimicrob Chemother 1996; 38: 523-527.
7. Romanelli G, Cravarezza P and the Italian Intramuscular Meropenem Study Group. Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. J Antimicrob Chemother 1995; 36 (suppl A): 109-119.
8. Mouton YJ, Beuscart C and the Meropenem Study Group. Empirical monotherapy with meropenem in serious bacterial infections. J Antimicrob Chemother 1995; 36 (suppl A): 145-156.
9. Harnacher J, Vogel F, Lichey J et al. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients - a comparison of meropenem and imipenem/cilastatin. J Antimicrob Chemother 1995; 36 (suppl A): 121-133.
10. Cox CE, Holloway WJ, Gekler RW. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients. Clin Infect Dis 1995; 21: 86-92.
11. Nichols RL, Smith JW, Geckler RW, Wilson SE. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections. South Med J 1995; 88: 397-400.
12. Hemsell D, Martens M. A multicenter study comparing intravenous meropenem with clindamycin plus gentamicin for the treatment of acute gynecologic and obstetric pelvic infections in hospitalized women. Clin Infect Dis 1997; 24 (suppl 2): S222-S230.
13. Schmutzhard E, Williams KJ, Vukmirovits G et al. A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. J Antimicrob Chemother 1995; 36 (suppl. A): 85-97.
14. Klugman KP, Dagan R and the Meropenem Meningitis Study Group. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Antimicrob Agents Chemother 1995; 39: 1140-1146.
15. Solberg CO, Sjursen H. Safety and efficacy of meropenem in patients with septicaemia: a randomised comparison with ceftazidime, alone or combined with amikacin. J Antimicrob Chemother 1995; 36 (suppl A): 157-166.
16. Cometta A, Calandra T, Gaya H et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996; 40: 1108-1115.
17. Boogaerts MA, Demuynck H, Mestdagh N et al. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother 1995; 36: 185-200.
18. Schito GC, Sanna A, Chezzi C et al. In-vitro activity of meropenem against clinical isolates in a multicentre study in Italy. J Antimicrob Chemother 1989; 24 (suppl A): 57-72.
19. Edwards JR, Turner PJ. Laboratory data which differentiate meropenem and imipenem. Scand J Infect Dis 1995; (suppl 96): 5-10.
20. Jones RN, Barry AL, Thornsberry C. In-vitro studies of meropenem. J Antimicrob Chemother 1989; 24 (suppl A): 9-29.
21. Wiseman LR, Wagstaff AJ. Brogden RN, Bryson HM. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1995; 50: 73-101.
22. Cho N, Araki H, Kimura T et al. Basic and clinical studies of meropenem in obstetrics and gynecology. Chemotherapy (Tokyo) 1992; 40 (suppl 1): 657-668.
23. Matsuda S. Clinical study of SM-7338 in obstetrics and gynecology. Chemotherapy (Tokyo) 1992; 40: 133.
24. Matsuda S. Pharmacokinetics and clinical studies of meropenem in the field of obstetrics and gynaecological infections. 8th Mediterranean Congress of Chemotherapy 1992; 24-29 May. J Chemother 1993; 5 (suppl 1): 143-146.
25. st European Congress of Chemotherapy, Glasgow, 14-17 May 1996, Abs F139.
26. Smyth ETM, Barr JG, Hogg GM. An assessment of hidden costs on total prescribing costs of courses of meropenem and imipenem/cilastatin. Br J Med Econ 1996; 10: 325-340.
27. Norrby SR, Newell PA, Faulkner KL, Lesky W. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother 1995; 36 (suppl A): 207-223.